Document is current
Any future updates will be listed below
-
Authors
Kuljanin, Miljan
Mitchell, Dylan C.
Schweppe, Devin K. https://orcid.org/0000-0002-3241-6276
Gikandi, Ajami S.
Nusinow, David P. https://orcid.org/0000-0002-7819-5261
Bulloch, Nathan J.
Vinogradova, Ekaterina V.
Wilson, David L. https://orcid.org/0000-0002-1922-427X
Kool, Eric T.
Mancias, Joseph D.
Cravatt, Benjamin F.
Gygi, Steven P. https://orcid.org/0000-0001-7626-0034
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (GM67945)
- License Information
-
More Information
Article History
Received: 19 January 2020
Accepted: 17 November 2020
First Online: 4 January 2021
Competing interests
: B.F.C. is a founder and scientific advisor of Vividion Therapeutics. S.P.G. is a member of the scientific advisory boards of Thermo Fisher Scientific, Cell Signaling Technology and Casma Therapeutics. S.P.G. is a founder of Cedilla Therapeutics and a scientific advisor to Third Rock Ventures. All other authors declare no competing interests.
